DDR and PARP inhibitors are complex therapeutic strategies. These educational programmes are developed by a multidisciplinary group of international clinician and scientist experts in DDR and PARP inhibition, to enable healthcare professionals around the world to increase their understanding of DDR and PARP inhibition and provide the best possible care to their patients.
The Steering Committee:
Please click on each programme to find out more
A review paper titled Moving from PARP Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy, published in the Journal of Clinical Oncology on May 3rd 2019.
Click to access: https://ascopubs.org/doi/abs/10.1200/JCO.18.02050
Click to access: Downloadable slides covering selected highlights for your own use
Reference guides to key aspects of DDR and PARP inhibition and their role in oncology. An accompanying slide deck summarises the key highlights from the DDR and PARP inhibition BluePrints. A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARP inhibition in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARP inhibitors.
AstraZeneca has provided a sponsorship grant towards this independent programme